TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00749177

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Healing options
Description: Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Healing options
Description: Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Healing options
Description: Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
Study: NCT01565876

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minkal- Auxiliary device to alleviate backload
Description: The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.~Then The participants will undergo heat tolerance test 5 times (in different days).~first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards.
Study: NCT03838276

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: AL 150 BPL100
Description: Roux-en-Y gastric bypass with 150cm of alimentary limb and 100cm of biliopancreatic limb

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AL 100 BPL 150
Description: Roux-en-Y gastric bypass with 100cm of alimentary limb and 150cm of biliopancreatic limb
Study: NCT02363803

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
Study: NCT00472758

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
Study: NCT02415842

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
Study: NCT02363803

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine
Description: lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Normal saline, approved for hypovolemia, and homeostasis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, approved for hypovolemia, and homeostasis.
Study: NCT02105779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Cognitive Training
Description: At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). \[Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Social Cognitive Training
Description: We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
Study: NCT00448903

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Bemiparin sodium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0,9%
Study: NCT01665209

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine Sulfate
Description: Morphine Sulfate 60mg Extended-release tablets
Study: NCT02415842

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.

Intervention type: OTHER
Intervention: Serum samples
Description: The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
Study: NCT03249662

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine 200 mg
Description: bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupivacaine 100 mg
Description: bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
Study: NCT03224559

Intervention type: DEVICE
Intervention: Transcranial Electrical Stimulation
Description: Transcranial Electrical Stimulation

Intervention type: DEVICE
Intervention: Transcranial Electrical Stimulation
Description: Transcranial Electrical Stimulation
Study: NCT03740893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: PART 1: Pre-operative exposure of 160mg AZD6738 to be administered orally twice daily on Days 5 -14 of the WOP.~PART 2: 12 months post-operative exposure to 160mg AZD6738 to be administered orally twice daily on Days 1 - 14 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: PART 1: Pre-operative exposure to 300mg of olaparib to be administered orally twice daily on Days 1-14 of the WOP.~PART 2: 12 months post-operative exposure to 300mg olaparib (2 x 150mg tablets) to be administered orally twice daily on a continuous schedule Day 1-28 of a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: PART 1: Pre-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of the WOP.~PART 2: 12 months post-operative exposure to 1500mg durvalumab to be administered via intravenous (IV) infusion on Day 1 only of a 28 day cycle.
Study: NCT01604993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinach soup
Description: 556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Asparagus soup
Description: 556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
Study: NCT03729271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be given during weeks 2-4

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose and lactulose hydrogen breath testing
Description: Subjects will undergo glucose and lactulose hydrogen breath tests for Small Intestinal Bacterial Overgrowth (SIBO) on consecutive days using a commercially available home base kits (Glucose Hydrogen Breath Test Collection Kit and Lactulose Hydrogen Breath Test Collection Kit for SIBO from Commonwealth Diagnostic International) prior to Rifaximin treatment and at week 13 of the study.
Study: NCT04097587

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: experimental group
Description: This program was carried out for 50 min/week over 8 weeks to empower parents with knowledge and self-efficacy about children's screen use, and motivate them to monitor and change their children's screen behaviors. Teaching strategies included lectures, group discussions, reflection, role playing, and peer sharing (Table 1). Topics included 1) parents' and children's screen use, 2) the relationship between network equipment and children's internet use, 3) the positive and negative effects of excessive screen use on children's physical and psychological development, 4) limiting screen use at mealtimes and bedtime, 5) strategies for screen-related devices, 6) alternative activities to screen use, such as board games and outdoor activities, 7) setting a target of appropriate screen times, and 8) encouraging the signing of a contract between parents and children to limit screen time. We also provided parents with a handbook of the course content.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: received standard school classes and usual activities offered at the kindergarten. Briefly, kindergarten activities included daily learning activities, outdoor activities, breakfast, lunch, snacks, and nap time.
Study: NCT03495583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early introduction
Description: Consumption of 2g/week of cow's milk, hen's egg, wheat, peanut, sesame and fish protein from 3 months of age (alongside breastfeeding)
Study: NCT01004276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New, improved smoking cessation management module
Description: The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
Study: NCT02730143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure
Description: Altitude exposure
Study: NCT03860558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Description: Participants will undergo a 12-week multidisciplinary program for weight control and intensive diabetes management. The program includes adjustments to diabetes medications to enhance weight reduction and improve glycemia, dietary modification, and activity instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Participants will not undergo an intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: Participants will not undergo an intervention.
Study: NCT03189056

Intervention type: DIAGNOSTIC_TEST
Intervention: Chagas serology
Description: IFI + ELISA method if no biological confirmation of chagas disease is in our possession

Intervention type: BIOLOGICAL
Intervention: Creatinina
Description: Plasmatic single mesure after consultation 1, to evaluate renal function

Intervention type: PROCEDURE
Intervention: Urodynamic exploration
Description: With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
Study: NCT00164697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting group
Description: Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
Study: NCT02437227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCT3833
Description: CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
Study: NCT04120103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Doll therapy
Description: The patient will then be given the doll to be used in the research by the caregiver and the researcher. Intervention group (accepting the baby) will be evaluated in terms of interaction with the baby, communication with employees and other patients and participation in daily life activities for 60 days. In addition, the agitation symptoms of the patients during the 60 days they spend with the baby will be evaluated by CMAI and cognitive level by MMSE.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine nursing care
Description: The nursing care provided by the institution was applied to the dementia patients in the routine nursing care group. Routine nursing care group interventions in the institution; Monitoring of life signs, application of drug treatments, participation in social activities such as listening to music, reading prayer, initiatives such as assisting patients in performing daily living activities.
Study: NCT04385329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shock wave therapy on plantar fascia extended to the gastrocnemius-soleus trigger points
Description: Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia and the gastrocnemius-soleus trigger points were clinically targeted and treated with a perpendicular technique.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave therapy on plantar fascia only
Description: Enrolled subjects were treated with focused shock wave therapy, once a week for three consecutive weeks, by a specialized physician with more than five years of expertise, using a device powered by a piezoelectric generator (PIEZOSON 100PLUS, Richard Wolf®). At each treatment session, with the patients lying in prone decubitus position, the enthesis of the plantar fascia was clinically targeted and treated with a perpendicular technique.
Study: NCT03069521

Intervention type: DEVICE
Group type: OTHER
Intervention: EndoArt® Artificial Endothelial Layer
Description: device is intended for use as an endothelial kearatoprosthesis
Study: NCT01649453

Intervention type: DEVICE
Intervention: Pathwork® Tissue of Origin Test
Study: NCT02721394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training
Description: Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training
Description: Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Communication Training
Description: Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
Study: NCT00918008

Intervention type: GENETIC
Intervention: Blood draw
Description: The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
Study: NCT02658591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crackers/pasta with added faba bean protein concentrate
Description: Protein concentrate treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crackers/pasta with added faba bean protein isolate
Description: Protein isolate treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crackers/pasta with added faba bean starch
Description: Starch treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crackers/pasta with added faba bean flour
Description: Flour treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Crackers/pasta with no faba bean fraction
Description: Control treatment
Study: NCT03661476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oculo-Motor Exercises (OME)
Description: Oculomotor Exercises (OME); The saccadic eye movement exercise included moving the eyes horizontally between two stationary targets while keeping the head still.~The smooth pursuit exercise included moving the target horizontally and tracking it with the eyes while keeping the head still.~The adaptation X1 exercise included moving the head horizontally while keeping the stationary target in focus.~The adaptation X2 exercise included moving the head and target in opposite directions horizontally while tracking the target with the eyes.
Study: NCT03635580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Negative control
Description: Untreated-control group
Study: NCT03866395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivabradine
Description: Ivabradine 5 mg twice a day
Study: NCT00998218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
Study: NCT02781740

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continous Positive Air Pressure Device

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Continous Positive Air Pressure Device
Study: NCT01122264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Administered orally for 24 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil Citrate
Description: Administered orally for 24 weeks.
Study: NCT04622800

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise, proprioceptive neuromuscular fasilition (PNF) techniques
Description: PNF applications are defined as the autogenous inhibition, reciprocal inhibition, stress relaxation and gate control theory. Anterior elevation / posterior depression will be performed in the form of repetitive contractions using anterior depression / posterior elevation patterns. There will be 10 repetitions, with a 2-minute rest break between each technique. The treatment will continue twice a week for a total of 6 weeks.
Study: NCT03751254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stellaris Elite
Description: The Stellaris and the Stellaris Elite platform will be used in myopic patients (axial length \> 25.0 mm) during cataract surgery
Study: NCT04140227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOV03
Description: 100% Perfluorohexyloctane